TARDBP and frontotemporal dementia: We believe this model could provide insight into cell biological mechanisms, leading to TDP-43 pathology and offer a platform for patient-tailored phenotype and therapeutic screening for FTD and ALS patients with suspected or confirmed TDP-43 proteinopathy.